Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1942 1
1948 2
1950 1
1951 4
1952 3
1953 1
1954 4
1955 1
1956 2
1957 2
1959 1
1961 2
1962 1
1963 7
1964 25
1965 13
1966 12
1967 17
1968 39
1969 33
1970 43
1971 47
1972 46
1973 52
1974 59
1975 62
1976 60
1977 64
1978 62
1979 84
1980 58
1981 76
1982 74
1983 76
1984 107
1985 115
1986 109
1987 117
1988 106
1989 152
1990 146
1991 159
1992 186
1993 194
1994 193
1995 153
1996 181
1997 204
1998 184
1999 227
2000 226
2001 252
2002 262
2003 296
2004 296
2005 314
2006 368
2007 369
2008 404
2009 384
2010 464
2011 433
2012 507
2013 507
2014 530
2015 598
2016 594
2017 642
2018 686
2019 691
2020 777
2021 888
2022 843
2023 846
2024 391

Text availability

Article attribute

Article type

Publication date

Search Results

14,755 results

Results by year

Filters applied: . Clear all
Page 1
Adherence to oral hormonal anticancer agents in breast cancer.
Gori S, Modena A, Foglietta J, Verzè M, Inno A, Casarin A, Russo A, Nicolis F. Gori S, et al. Tumori. 2023 Jun;109(3):262-268. doi: 10.1177/03008916221096183. Epub 2022 May 21. Tumori. 2023. PMID: 35603579 Review.
Medical oncologists must therefore seek to optimize patient adherence. Breast cancer patients, particularly, are often treated with oral hormonal anticancer agents. In this review, we summarized evidence about adherence of breast cancer patients …
Medical oncologists must therefore seek to optimize patient adherence. Breast cancer patients, particularly, are often treated …
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, Loibl S, Bonanni B, Evans DG, Howell A; IBIS-II investigators. Cuzick J, et al. Lancet. 2020 Jan 11;395(10218):117-122. doi: 10.1016/S0140-6736(19)32955-1. Epub 2019 Dec 12. Lancet. 2020. PMID: 31839281 Free PMC article. Clinical Trial.
BACKGROUND: Two large clinical trials have shown a reduced rate of breast cancer development in high-risk women in the initial 5 years of follow-up after use of aromatase inhibitors (MAP.3 and International Breast Cancer Intervention Study II [IBIS-II] …
BACKGROUND: Two large clinical trials have shown a reduced rate of breast cancer development in high-risk women in the initial …
Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers.
Lin C, Clark R, Tu P, Bosworth HB, Zullig LL. Lin C, et al. Breast Cancer Res Treat. 2017 Sep;165(2):247-260. doi: 10.1007/s10549-017-4317-2. Epub 2017 Jun 1. Breast Cancer Res Treat. 2017. PMID: 28573448 Review.
PURPOSE: In the past decade, there has been an increase in the development and use of oral anti-cancer medications (OAMs), especially for breast cancer-the most prevalent cancer in women. ...Our goal was to identify potentially modifiable psycho …
PURPOSE: In the past decade, there has been an increase in the development and use of oral anti-cancer medications (OAMs), esp …
Factors for the Primary Prevention of Breast Cancer: A Meta-Analysis of Prospective Cohort Studies.
Poorolajal J, Heidarimoghis F, Karami M, Cheraghi Z, Gohari-Ensaf F, Shahbazi F, Zareie B, Ameri P, Sahraee F. Poorolajal J, et al. J Res Health Sci. 2021 Jul 20;21(3):e00520. doi: 10.34172/jrhs.2021.57. J Res Health Sci. 2021. PMID: 34698654 Free PMC article.
BACKGROUND: This report provided the effect of 15 preventable factors on the risk of breast cancer incidence. STUDY DESIGN: A systematic review and meta-analysis. ...Prospective cohort studies addressing the associations between breast cancer and 15 fa …
BACKGROUND: This report provided the effect of 15 preventable factors on the risk of breast cancer incidence. STUDY DESIGN: A …
The impact of oral contraceptive use on breast cancer risk: State of the art and future perspectives in the era of 4P medicine.
Bonfiglio R, Di Pietro ML. Bonfiglio R, et al. Semin Cancer Biol. 2021 Jul;72:11-18. doi: 10.1016/j.semcancer.2020.10.008. Epub 2021 Jan 14. Semin Cancer Biol. 2021. PMID: 33454355 Review.
Nevertheless, data about the association between the assumption of oral contraceptives and breast cancer incidence are still controversial and not conclusive. Given the public health importance of breast cancer and the popularity of hormonal "pi …
Nevertheless, data about the association between the assumption of oral contraceptives and breast cancer incidence are …
[Oral contraception and the risk of breast cancer. Review of the literature].
Nagykálnai T, Landherr L. Nagykálnai T, et al. Magy Onkol. 2018 Dec 12;62(4):258-263. Epub 2018 Sep 10. Magy Onkol. 2018. PMID: 30540869 Free article. Review. Hungarian.
Previous studies of breast cancer risk show inconsistent findings - from zero elevation to approximately 30%-40% increase in risk. The beneficial effect on ovarian and endometrial cancer risk is apparent. In this literature review we attempt to determine effe …
Previous studies of breast cancer risk show inconsistent findings - from zero elevation to approximately 30%-40% increase in r …
Effective oral chemotherapy for breast cancer: pillars of strength.
Findlay M, von Minckwitz G, Wardley A. Findlay M, et al. Ann Oncol. 2008 Feb;19(2):212-22. doi: 10.1093/annonc/mdm285. Epub 2007 Nov 15. Ann Oncol. 2008. PMID: 18006898 Free article. Review.
Important issues include patient preference, efficacy, compliance, bioavailability, reimbursement, use in special patient populations, financial and staff time savings and flexibility of dosing. We review data for traditional oral agents (e.g. cyclophosphamide, methotrexat …
Important issues include patient preference, efficacy, compliance, bioavailability, reimbursement, use in special patient populations, finan …
Oral contraceptives and breast cancer: review of the epidemiologic literature.
Thomas DB. Thomas DB. Contraception. 1991 Jun;43(6):597-642. doi: 10.1016/0010-7824(91)90006-2. Contraception. 1991. PMID: 1868735 Review.
Limited evidence suggests a possible small increase in risk in users of oral contraceptives in developing countries, and further studies of breast cancer and oral contraceptives in low risk populations are warranted. Oral contraceptives may enha …
Limited evidence suggests a possible small increase in risk in users of oral contraceptives in developing countries, and further stud …
Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective.
Hernando C, Ortega-Morillo B, Tapia M, Moragón S, Martínez MT, Eroles P, Garrido-Cano I, Adam-Artigues A, Lluch A, Bermejo B, Cejalvo JM. Hernando C, et al. Int J Mol Sci. 2021 Jul 22;22(15):7812. doi: 10.3390/ijms22157812. Int J Mol Sci. 2021. PMID: 34360578 Free PMC article. Review.
Estrogen receptor-positive (ER+) is the most common subtype of breast cancer. Endocrine therapy is the fundamental treatment against this entity, by directly or indirectly modifying estrogen production. ...In this scenario, selective estrogen receptor degraders/down …
Estrogen receptor-positive (ER+) is the most common subtype of breast cancer. Endocrine therapy is the fundamental treatment a …
Oral and maxillofacial metastasis of male breast cancer: Report of a rare case and literature review.
de Almeida Freire N, de Andrade BAB, Silva Canedo NH, Agostini M, Romañach MJ. de Almeida Freire N, et al. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019 Jan;127(1):e18-e22. doi: 10.1016/j.oooo.2018.05.006. Epub 2018 May 30. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019. PMID: 29934067 Review.
Oral and maxillofacial metastatic tumors are uncommon, with the breast, prostate, lung, and kidney representing the most common primary sites. Less than 1% of all breast cancers occur in male patients, and to date, only 8 cases of metastatic breast ade …
Oral and maxillofacial metastatic tumors are uncommon, with the breast, prostate, lung, and kidney representing the most commo …
14,755 results
You have reached the last available page of results. Please see the User Guide for more information.

Searches related to "breast cancer oral"